Gilead price target raised to $155 from $152 at Truist
Truist analyst Gregory Renza raised the firm’s price target on Gilead (GILD) to $155 from $152 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 earnings in Biotech. Reactivity to regulatory and policy shifts across the sector continues to ease, and the firm also notes a recent pickup in deal activity, which has the potential to build momentum through the remainder of the year into mid-terms, the analyst tells investors in a research note. For the company, the firm is looking for its management commentary on Yeztugo launch strategy and payer access dynamics in U.S./EU markets and any anito-cel launch preparation updates ahead of the December 23, 2026 PDUFA, Truist added.
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
Disclaimer & DisclosureReport an Issue
- Gilead price target raised to $155 from $152 at Truist
- Balancing Strategic Oncology Expansion and Execution Risk: Why Gilead’s Tubulis Deal Supports a Hold Rating
- Gilead Sciences: Strategic Oncology Expansion and Undervalued Growth Opportunity Driving Buy Rating
- Gilead’s Tubulis Acquisition: Building an ADC Oncology Franchise and Enhancing Risk‑Reward for GILD Shares
- Leerink says Tubulis deal highlights value of ADC platforms like Sutro’s
